Events

SEMIC 2026 Conference
NOV
Mon
30

Starts in 2 months from now

Location

Dublin (Ireland)

Royal Dublin Society, Merrion Road, Ballsbridge, Dublin 4 D04 AK83, Ireland
Programmes
Digital, Industry & Space Semiconductors

The 2026 edition of the SEMIC, a conference on semantic interoperability and digital government will take place under the theme 'Interoperable Europe driving competitiveness'. 

The event is organised by the European Commission’s Directorate-General for Digital Services (DG DIGIT) with the support of the Irish Presidency of the Council of the European Union. It will bring together public sector professionals, policymakers, researchers, industry representatives and interoperability practitioners from across Europe focussing on topics such as policy, digital public services, data, AI, GovTech, open source or digital transformation.

More information on the event and the possibility to register can be found on the official SEMIC 2026 website.

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.